InsiderTrades.com logo
Elisabeth Bjork net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Elisabeth Bjork Biography and Net Worth

Director of Pharvaris

Dr. Bjӧrk has been a director since December 2021. Dr. Bjӧrk was Senior Vice President, Late-stage Development, Cardiovascular, Renal and Metabolism (CVRM), BioPharmaceuticals R&D at AstraZeneca and led the global development of medicines within this area for over 10 years. Throughout her career at AstraZeneca which began in 2002, she has gained broad drug development experience covering clinical development phase I-IV, large outcomes programs, major global filings and health authority interactions, and commercial strategy/implementation. Dr. Bjӧrk is an endocrinologist by training and an associate professor of medicine at Uppsala University, Sweden. She is also a board member of Rocket Pharmaceuticals, Vicore Pharma AB, Camurus AB, Betula Consulting AB, and NodThera.

What is Elisabeth Bjork's net worth?

The estimated net worth of Elisabeth Bjork is at least $453.34 thousand as of May 20th, 2026. Bjork owns 15,167 shares of Pharvaris stock worth more than $453,342 as of June 3rd. This net worth estimate does not reflect any other assets that Bjork may own. Learn More about Elisabeth Bjork's net worth.

How do I contact Elisabeth Bjork?

The corporate mailing address for Bjork and other Pharvaris executives is , , . Pharvaris can also be reached via phone at 31-71-203-6410 and via email at [email protected]. Learn More on Elisabeth Bjork's contact information.

Has Elisabeth Bjork been buying or selling shares of Pharvaris?

During the past quarter, Elisabeth Bjork has sold $293,200.00 in Pharvaris stock. Most recently, Elisabeth Bjork sold 10,000 shares of the business's stock in a transaction on Wednesday, May 20th. The shares were sold at an average price of $29.32, for a transaction totalling $293,200.00. Following the completion of the sale, the director now directly owns 15,167 shares of the company's stock, valued at $444,696.44. Learn More on Elisabeth Bjork's trading history.

Who are Pharvaris' active insiders?

Pharvaris' insider roster includes Elisabeth Bjork (Director), Anne Lesage (Chief Early Development Officer), Anne Lesage (Insider), Peng Lu (Chief Medical Officer), Berndt Modig (Chief Executive Officer, Director (CH)), David Nassif (CFO), and Anna Nijdam (Insider). Learn More on Pharvaris' active insiders.

Are insiders buying or selling shares of Pharvaris?

In the last twelve months, insiders at the sold shares 24 times. They sold a total of 209,948 shares worth more than $6,268,140.96. The most recent insider tranaction occured on May, 22nd when insider Anna Nijdam sold 5,501 shares worth more than $169,100.74. Learn More about insider trades at Pharvaris.

Information on this page was last updated on 5/22/2026.

Elisabeth Bjork Insider Trading History at Pharvaris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/20/2026Sell10,000$29.32$293,200.0015,167View SEC Filing Icon  
See Full Table

Elisabeth Bjork Buying and Selling Activity at Pharvaris

This chart shows Elisabeth Bjork's buying and selling at Pharvaris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pharvaris Company Overview

Pharvaris logo
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More

Today's Range

Now: $30.14
Low: $28.80
High: $30.50

50 Day Range

MA: $28.86
Low: $25.34
High: $32.94

2 Week Range

Now: $30.14
Low: $15.91
High: $33.33

Volume

703,962 shs

Average Volume

233,293 shs

Market Capitalization

$1.97 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A